These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 38959542)

  • 1. CD44/PD-L1-mediated networks in drug resistance and immune evasion of breast cancer stem cells: Promising targets of natural compounds.
    Malla R; Jyosthsna K; Rani G; Purnachandra Nagaraju G
    Int Immunopharmacol; 2024 Sep; 138():112613. PubMed ID: 38959542
    [TBL] [Abstract][Full Text] [Related]  

  • 2. BRD4/nuclear PD-L1/RelB circuit is involved in the stemness of breast cancer cells.
    Kim SL; Choi HS; Lee DS
    Cell Commun Signal; 2023 Nov; 21(1):315. PubMed ID: 37924094
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differentiation of breast cancer stem cells by knockdown of CD44: promising differentiation therapy.
    Pham PV; Phan NL; Nguyen NT; Truong NH; Duong TT; Le DV; Truong KD; Phan NK
    J Transl Med; 2011 Dec; 9():209. PubMed ID: 22152097
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gastric cancer mesenchymal stem cells regulate PD-L1-CTCF enhancing cancer stem cell-like properties and tumorigenesis.
    Sun L; Huang C; Zhu M; Guo S; Gao Q; Wang Q; Chen B; Li R; Zhao Y; Wang M; Chen Z; Shen B; Zhu W
    Theranostics; 2020; 10(26):11950-11962. PubMed ID: 33204322
    [No Abstract]   [Full Text] [Related]  

  • 5. Targeting treatment-resistant breast cancer stem cells with FKBPL and its peptide derivative, AD-01, via the CD44 pathway.
    McClements L; Yakkundi A; Papaspyropoulos A; Harrison H; Ablett MP; Jithesh PV; McKeen HD; Bennett R; Donley C; Kissenpfennig A; McIntosh S; McCarthy HO; O'Neill E; Clarke RB; Robson T
    Clin Cancer Res; 2013 Jul; 19(14):3881-93. PubMed ID: 23741069
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PD-L1 promotes colorectal cancer stem cell expansion by activating HMGA1-dependent signaling pathways.
    Wei F; Zhang T; Deng SC; Wei JC; Yang P; Wang Q; Chen ZP; Li WL; Chen HC; Hu H; Cao J
    Cancer Lett; 2019 May; 450():1-13. PubMed ID: 30776481
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CD44 Promotes PD-L1 Expression and Its Tumor-Intrinsic Function in Breast and Lung Cancers.
    Kong T; Ahn R; Yang K; Zhu X; Fu Z; Morin G; Bramley R; Cliffe NC; Xue Y; Kuasne H; Li Q; Jung S; Gonzalez AV; Camilleri-Broet S; Guiot MC; Park M; Ursini-Siegel J; Huang S
    Cancer Res; 2020 Feb; 80(3):444-457. PubMed ID: 31722999
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diallyl Disulfide Inhibits Breast Cancer Stem Cell Progression and Glucose Metabolism by Targeting CD44/PKM2/AMPK Signaling.
    Xie X; Huang X; Tang H; Ye F; Yang L; Guo X; Tian Z; Xie X; Peng C; Xie X
    Curr Cancer Drug Targets; 2018; 18(6):592-599. PubMed ID: 29110616
    [TBL] [Abstract][Full Text] [Related]  

  • 9. STAT3 as a promising chemoresistance biomarker associated with the CD44
    Moreira MP; da Conceição Braga L; Cassali GD; Silva LM
    Exp Cell Res; 2018 Feb; 363(2):283-290. PubMed ID: 29352988
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ADAM protease inhibition overcomes resistance of breast cancer stem-like cells to γδ T cell immunotherapy.
    Dutta I; Dieters-Castator D; Papatzimas JW; Medina A; Schueler J; Derksen DJ; Lajoie G; Postovit LM; Siegers GM
    Cancer Lett; 2021 Jan; 496():156-168. PubMed ID: 33045304
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cancer stem cell in breast cancer therapeutic resistance.
    Bai X; Ni J; Beretov J; Graham P; Li Y
    Cancer Treat Rev; 2018 Sep; 69():152-163. PubMed ID: 30029203
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MiR-873/PD-L1 axis regulates the stemness of breast cancer cells.
    Gao L; Guo Q; Li X; Yang X; Ni H; Wang T; Zhao Q; Liu H; Xing Y; Xi T; Zheng L
    EBioMedicine; 2019 Mar; 41():395-407. PubMed ID: 30803931
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Small cell lung cancer stem cells display mesenchymal properties and exploit immune checkpoint pathways in activated cytotoxic T lymphocytes.
    Kursunel MA; Taskiran EZ; Tavukcuoglu E; Yanik H; Demirag F; Karaosmanoglu B; Ozbay FG; Uner A; Esendagli D; Kizilgoz D; Yilmaz U; Esendagli G
    Cancer Immunol Immunother; 2022 Feb; 71(2):445-459. PubMed ID: 34228218
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Propofol Reduced Mammosphere Formation of Breast Cancer Stem Cells via PD-L1/Nanog
    Zhang X; Li F; Zheng Y; Wang X; Wang K; Yu Y; Zhao H
    Oxid Med Cell Longev; 2019; 2019():9078209. PubMed ID: 30906504
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Circular RNA circ-CPA4/ let-7 miRNA/PD-L1 axis regulates cell growth, stemness, drug resistance and immune evasion in non-small cell lung cancer (NSCLC).
    Hong W; Xue M; Jiang J; Zhang Y; Gao X
    J Exp Clin Cancer Res; 2020 Aug; 39(1):149. PubMed ID: 32746878
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Breast cancer stem cells, heterogeneity, targeting therapies and therapeutic implications.
    Zeng X; Liu C; Yao J; Wan H; Wan G; Li Y; Chen N
    Pharmacol Res; 2021 Jan; 163():105320. PubMed ID: 33271295
    [TBL] [Abstract][Full Text] [Related]  

  • 17. WNT signaling modulates PD-L1 expression in the stem cell compartment of triple-negative breast cancer.
    Castagnoli L; Cancila V; Cordoba-Romero SL; Faraci S; Talarico G; Belmonte B; Iorio MV; Milani M; Volpari T; Chiodoni C; Hidalgo-Miranda A; Tagliabue E; Tripodo C; Sangaletti S; Di Nicola M; Pupa SM
    Oncogene; 2019 May; 38(21):4047-4060. PubMed ID: 30705400
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activation of Matrix Hyaluronan-Mediated CD44 Signaling, Epigenetic Regulation and Chemoresistance in Head and Neck Cancer Stem Cells.
    Bourguignon LYW; Earle C; Shiina M
    Int J Mol Sci; 2017 Aug; 18(9):. PubMed ID: 28837080
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PD-L1 is highly expressed in ovarian cancer and associated with cancer stem cells populations expressing CD44 and other stem cell markers.
    Alwosaibai K; Aalmri S; Mashhour M; Ghandorah S; Alshangiti A; Azam F; Selwi W; Gharaibeh L; Alatawi Y; Alruwaii Z; Alsaab HO
    BMC Cancer; 2023 Jan; 23(1):13. PubMed ID: 36604635
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metformin-induced preferential killing of breast cancer initiating CD44+CD24-/low cells is sufficient to overcome primary resistance to trastuzumab in HER2+ human breast cancer xenografts.
    Cufi S; Corominas-Faja B; Vazquez-Martin A; Oliveras-Ferraros C; Dorca J; Bosch-Barrera J; Martin-Castillo B; Menendez JA
    Oncotarget; 2012 Apr; 3(4):395-8. PubMed ID: 22565037
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.